FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036968137> ?p ?o ?g. }

• W2036968137 endingPage "58" @default.
• W2036968137 startingPage "50" @default.
• W2036968137 abstract "The clinical importance of low serum levels of high-density lipoprotein (HDL) cholesterol is often under-recognized and underappreciated as a risk factor for premature atherosclerosis as well as for cardiovascular morbidity and mortality. Low serum levels of HDL are frequently encountered, especially in patients who are obese or have the metabolic syndrome. In prospective epidemiologic studies, every 1-mg/dL increase in HDL is associated with a 2% to 3% decrease in coronary artery disease risk, independent of low-density lipoprotein (LDL) cholesterol and triglyceride (TG) levels. The primary mechanism for this protective effect is believed to be reverse cholesterol transport, but several other anti-inflammatory, antithrombotic, and antiproliferative functions for HDL have also been identified. In recognition of these antiatherogenic effects, recent guidelines have increased the threshold for defining low levels of HDL for both men and women. The first step in achieving these revised targets is therapeutic lifestyle changes. When these measures are inadequate, pharmacotherapy specific to the patient’s lipid profile should be instituted. Niacin therapy, currently the most effective means for raising HDL levels, should be initiated in patients with isolated low HDL (HDL <40 mg/dL, LDL and non-HDL at or below National Cholesterol Education Program (NCEP) targets based on global cardiovascular risk evaluation). Patients who have both low HDL and elevated LDL should receive a statin or statin-niacin combination therapy, and patients with concomitant low HDL and elevated TGs should receive a fibrate initially, with a statin, niacin, or ezetimibe added thereafter as needed to help attain NCEP lipoprotein targets. The clinical importance of low serum levels of high-density lipoprotein (HDL) cholesterol is often under-recognized and underappreciated as a risk factor for premature atherosclerosis as well as for cardiovascular morbidity and mortality. Low serum levels of HDL are frequently encountered, especially in patients who are obese or have the metabolic syndrome. In prospective epidemiologic studies, every 1-mg/dL increase in HDL is associated with a 2% to 3% decrease in coronary artery disease risk, independent of low-density lipoprotein (LDL) cholesterol and triglyceride (TG) levels. The primary mechanism for this protective effect is believed to be reverse cholesterol transport, but several other anti-inflammatory, antithrombotic, and antiproliferative functions for HDL have also been identified. In recognition of these antiatherogenic effects, recent guidelines have increased the threshold for defining low levels of HDL for both men and women. The first step in achieving these revised targets is therapeutic lifestyle changes. When these measures are inadequate, pharmacotherapy specific to the patient’s lipid profile should be instituted. Niacin therapy, currently the most effective means for raising HDL levels, should be initiated in patients with isolated low HDL (HDL <40 mg/dL, LDL and non-HDL at or below National Cholesterol Education Program (NCEP) targets based on global cardiovascular risk evaluation). Patients who have both low HDL and elevated LDL should receive a statin or statin-niacin combination therapy, and patients with concomitant low HDL and elevated TGs should receive a fibrate initially, with a statin, niacin, or ezetimibe added thereafter as needed to help attain NCEP lipoprotein targets." @default.
• W2036968137 created "2016-06-24" @default.
• W2036968137 creator A5054876477 @default.
• W2036968137 date "2005-11-01" @default.
• W2036968137 modified "2023-10-16" @default.
• W2036968137 title "High-Density Lipoprotein As a Therapeutic Target: Clinical Evidence and Treatment Strategies" @default.
• W2036968137 cites W1552709412 @default.
• W2036968137 cites W1570964865 @default.
• W2036968137 cites W1965296791 @default.
• W2036968137 cites W1965545632 @default.
• W2036968137 cites W1978318375 @default.
• W2036968137 cites W1987025558 @default.
• W2036968137 cites W1988179941 @default.
• W2036968137 cites W2010378180 @default.
• W2036968137 cites W2011762309 @default.
• W2036968137 cites W2021391816 @default.
• W2036968137 cites W2024865167 @default.
• W2036968137 cites W2027754732 @default.
• W2036968137 cites W2033762664 @default.
• W2036968137 cites W2041696629 @default.
• W2036968137 cites W2045048750 @default.
• W2036968137 cites W2046991199 @default.
• W2036968137 cites W2047410519 @default.
• W2036968137 cites W2050601245 @default.
• W2036968137 cites W2053155814 @default.
• W2036968137 cites W2053365438 @default.
• W2036968137 cites W2054762675 @default.
• W2036968137 cites W2055012743 @default.
• W2036968137 cites W2055318521 @default.
• W2036968137 cites W2055395645 @default.
• W2036968137 cites W2057674977 @default.
• W2036968137 cites W2058218400 @default.
• W2036968137 cites W2059022881 @default.
• W2036968137 cites W2059613678 @default.
• W2036968137 cites W2066288680 @default.
• W2036968137 cites W2070855777 @default.
• W2036968137 cites W2077760013 @default.
• W2036968137 cites W2078807483 @default.
• W2036968137 cites W2081180316 @default.
• W2036968137 cites W2090984426 @default.
• W2036968137 cites W2095507444 @default.
• W2036968137 cites W2101393751 @default.
• W2036968137 cites W2106340207 @default.
• W2036968137 cites W2106839512 @default.
• W2036968137 cites W2108054626 @default.
• W2036968137 cites W2109063792 @default.
• W2036968137 cites W2111525459 @default.
• W2036968137 cites W2114810042 @default.
• W2036968137 cites W2115572248 @default.
• W2036968137 cites W2117092539 @default.
• W2036968137 cites W2117416880 @default.
• W2036968137 cites W2119065130 @default.
• W2036968137 cites W2127510556 @default.
• W2036968137 cites W2129750583 @default.
• W2036968137 cites W2132181466 @default.
• W2036968137 cites W2134267700 @default.
• W2036968137 cites W2135631433 @default.
• W2036968137 cites W2137188051 @default.
• W2036968137 cites W2144692487 @default.
• W2036968137 cites W2145034104 @default.
• W2036968137 cites W2150797190 @default.
• W2036968137 cites W2151722413 @default.
• W2036968137 cites W2154704322 @default.
• W2036968137 cites W2160689800 @default.
• W2036968137 cites W2160945880 @default.
• W2036968137 cites W2164576143 @default.
• W2036968137 cites W2164724187 @default.
• W2036968137 cites W2165441794 @default.
• W2036968137 cites W2169033201 @default.
• W2036968137 cites W2313266021 @default.
• W2036968137 cites W2328529137 @default.
• W2036968137 cites W2337032743 @default.
• W2036968137 cites W2341665659 @default.
• W2036968137 cites W2400712338 @default.
• W2036968137 cites W2725187802 @default.
• W2036968137 cites W4210329910 @default.
• W2036968137 cites W424467158 @default.
• W2036968137 cites W4247129995 @default.
• W2036968137 cites W4248705054 @default.
• W2036968137 cites W4296976561 @default.
• W2036968137 cites W99741135 @default.
• W2036968137 doi "https://doi.org/10.1016/j.amjcard.2005.08.008" @default.
• W2036968137 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16291015" @default.
• W2036968137 hasPublicationYear "2005" @default.
• W2036968137 type Work @default.
• W2036968137 sameAs 2036968137 @default.
• W2036968137 citedByCount "83" @default.
• W2036968137 countsByYear W20369681372012 @default.
• W2036968137 countsByYear W20369681372013 @default.
• W2036968137 countsByYear W20369681372014 @default.
• W2036968137 countsByYear W20369681372015 @default.
• W2036968137 countsByYear W20369681372016 @default.
• W2036968137 countsByYear W20369681372017 @default.
• W2036968137 countsByYear W20369681372018 @default.
• W2036968137 countsByYear W20369681372019 @default.
• W2036968137 countsByYear W20369681372021 @default.
• W2036968137 countsByYear W20369681372023 @default.
• W2036968137 crossrefType "journal-article" @default.

• next